Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5445993 | 0.98 | KDM4E (0.31) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| SCHEMBL5444525 | 0.94 | — | — | |
| Bromide SCHEMBL5443574 | 0.88 | KDM4E (0.30) | KDM4EALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL5445998 | 0.88 | ACHE (0.34) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5450114 | 0.85 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL5449865 | 0.82 | — | — | |
| Bromide SCHEMBL1882248 | 0.82 | KDM4E (0.39) | KDM4EALDH1A1HPGD | |
| Bromide SCHEMBL3408562 | 0.80 | HTT (0.44) | — | |
| SCHEMBL12638817 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| Bromide SCHEMBL3408580 | 0.79 | HTT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1658297-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005016940-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | KDM4E 1831/4885ALDH1A1 1833/4885MEN1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.